Table 7.
Treatment and outcomes.
| Publication (reference) | mPAP (S/D) before therapy (mmHg) | mPAP (S/D) after therapy (mmHg) | CI before therapy (L/min/m2) | CI after therapy (L/min/m2) | Primary malignancy | Therapy | Survival (months) |
|---|---|---|---|---|---|---|---|
| Publications showing improvement in PH and survival | |||||||
| Fukada et al.33 | 60 (93/39) | 50 (87/30) | 1.63 | 2.83 | Breast adenocarcinoma | Imatinib (200 mg/d*), tadalafil 40 mg | 1–¾ |
| Higo et al.15 | 48 (77/31) | 35 (69/17) | 1.82 | 4.64 | Colon adenocarcinoma | Imatinib (50 mg/day†), bevacizumab (5 mg/kg), S-1‡ (100 mg/day) | 12 |
| Kubota et al.32 | 46 (70/31) | 22 (35/12) | NA | NA | Gastric adenocarcinoma | Imatinib (200 mg/d), bosentan (62.5 mg), tadalafil (40 mg), TS-1, oxaliplatin | 7 |
| Ogawa et al.31** | ∼ 47 | ∼ 23 | ∼ 2 | ∼ 4 | Gastric and duodenal adenocarcinomas | Bosentan, epoprostanol (3.8 ng/kg/min) catecholamines, imatinib (100 mg/d), TS-1 | 10 |
| Minatsuki et al.30 | 48 | 13 | 2.69 | 2.71 | Gastric adenocarcinoma | Imatinib (200 mg/d), tadalafil (20 mg), sildenafil (60 mg), ambrisentan (10 mg) | 13 |
| Publications showing improved survival without information regarding PH | |||||||
| Miyano et al.10 | NA | NA | NA | NA | Gastric adenocarcinoma | S-1, dexamethasone, warfarin, aspirin | 7†† |
| Kayatani et al.6 | NA | NA | NA | NA | Adenocarcinoma of unknown origin | S-1, cisplatin, S-1, gemcitabine 10 months later with recurrence of symptoms | 15 |
| Publications showing no improvement in PH with associated survival | |||||||
| Purga et al.34 | 37 (64/22) | 38 (70/22) | 1.7 | 2.0 | Ovarian adenocarcinoma | iNO, dobutamine, dopamine, vasopressin, treprostinil | 1 |
| Endicott-Yazdani et al.45 | 37 (70/30) | NA (worsening PH but pressures not reported) | NA | NA | Gastric adenocarcinoma | Epoprostanol | 2.5 |
Administered as part of a clinical trial with approval from the institutional review board. Imatinib dose was increased to 400 mg after reduction in PAP.
Imatinib started at 50 mg/day and gradually increased to 200 mg/day.
S-1 consists of tegafur, gimeracil, and oteracil potassium.
Measurements are estimates because they were extrapolated from a graph and values of mPAP and CI were not explicitly stated
PH was not present in this case on echocardiography but it is unclear when during the patient's clinical course the echocardiography was performed. The patient was followed for seven months, at which time she was doing well but no further follow-up was published.
CI, cardiac index; iNO, inhaled nitric oxide; mPAP, mean pulmonary artery pressure; NA, not available; S/D, systolic/diastolic; TS-1, titanium silicate 1.